Literature DB >> 25505279

Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism.

Simone Bürgler1, Aleix Gimeno2, Anna Parente-Ribes3, Dong Wang3, Audun Os3, Stephen Devereux4, Peter Jebsen5, Bjarne Bogen6, Geir E Tjønnfjord7, Ludvig A Munthe8.   

Abstract

Chronic lymphocytic leukemia (CLL) is a B cell malignancy associated with increased levels of inflammatory cytokines. Similarly, expression of CD38 on CLL cells correlates with CLL cell survival and proliferation, but the mechanisms that regulate CD38 expression and inflammatory cytokines remain unclear. We have recently demonstrated that patients have CLL-specific Th cells that support CLL proliferation. In this article, we show that CLL cells attract such Th cells, thereby establishing an Ag-dependent collaboration. Blocking experiments performed in vitro as wells as in vivo, using a xenograft model, revealed that secretion of IFN-γ was a major mechanism by which CLL-specific Th cells increased CD38 on CLL cells. The expression of the transcription factor T-bet in peripheral blood CLL cells significantly correlated with CD38 expression, and transient transfection of CLL cells with T-bet resulted in T-bet(hi)CD38(hi) cells. Finally, chromatin immunoprecipitation experiments revealed that T-bet can bind to regulatory regions of the CD38 gene. These data suggest that CLL cells attract CLL-specific Th cells and initiate a positive feedback loop with upregulation of T-bet, CD38, and type 1 chemokines allowing further recruitment of Th cells and increased type 1 cytokine secretion. This insight provides a cellular and molecular mechanism that links the inflammatory signature observed in CLL pathogenesis with CD38 expression and aggressive disease and suggests that targeting the IFN-γ/IFN-γR/JAK/STAT/T-bet/CD38 pathway could play a role in the therapy of CLL.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25505279     DOI: 10.4049/jimmunol.1401350

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.

Authors:  Anna Parente-Ribes; Sigrid S Skånland; Simone Bürgler; Audun Os; Dong Wang; Bjarne Bogen; Geir E Tjønnfjord; Kjetil Taskén; Ludvig A Munthe
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

2.  Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.

Authors:  Qingsong Yin; Mariela Sivina; Harlan Robins; Erik Yusko; Marissa Vignali; Susan O'Brien; Michael J Keating; Alessandra Ferrajoli; Zeev Estrov; Nitin Jain; William G Wierda; Jan A Burger
Journal:  J Immunol       Date:  2017-01-11       Impact factor: 5.422

3.  Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia.

Authors:  Iris de Weerdt; Vera van Hoeven; J Marius Munneke; Sanne Endstra; Tom Hofland; Mette D Hazenberg; Arnon P Kater
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

4.  Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.

Authors:  Piers E M Patten; Gerardo Ferrer; Shih-Shih Chen; Rita Simone; Sonia Marsilio; Xiao-Jie Yan; Zachary Gitto; Chaohui Yuan; Jonathan E Kolitz; Jacqueline Barrientos; Steven L Allen; Kanti R Rai; Thomas MacCarthy; Charles C Chu; Nicholas Chiorazzi
Journal:  JCI Insight       Date:  2016-04-07

5.  Death-associated Protein Kinase-1 Expression and Autophagy in Chronic Lymphocytic Leukemia Are Dependent on Activating Transcription Factor-6 and CCAAT/Enhancer-binding Protein-β.

Authors:  Padmaja Gade; Amy S Kimball; Angela C DiNardo; Priyamvada Gangwal; Douglas D Ross; H Scott Boswell; Susan K Keay; Dhananjaya V Kalvakolanu
Journal:  J Biol Chem       Date:  2016-09-02       Impact factor: 5.157

6.  Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues.

Authors:  Bola S Hanna; Philipp M Roessner; Haniyeh Yazdanparast; Dolors Colomer; Elias Campo; Sabrina Kugler; Deyan Yosifov; Stephan Stilgenbauer; Manfred Schmidt; Richard Gabriel; Peter Lichter; Martina Seiffert
Journal:  Leukemia       Date:  2018-09-28       Impact factor: 11.528

Review 7.  PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).

Authors:  Klaus Okkenhaug; Jan A Burger
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

Review 8.  Pediatric precursor B acute lymphoblastic leukemia: are T helper cells the missing link in the infectious etiology theory?

Authors:  Simone Bürgler; David Nadal
Journal:  Mol Cell Pediatr       Date:  2017-05-16

Review 9.  Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.

Authors:  Klaus Okkenhaug; Mariona Graupera; Bart Vanhaesebroeck
Journal:  Cancer Discov       Date:  2016-09-21       Impact factor: 39.397

10.  The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.

Authors:  Daisuke Ogiya; Jiye Liu; Hiroto Ohguchi; Keiji Kurata; Mehmet K Samur; Yu-Tzu Tai; Sophia Adamia; Kiyoshi Ando; Teru Hideshima; Kenneth C Anderson
Journal:  Blood       Date:  2020-11-12       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.